Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: FluimediX Closes $1.1M Financing Round

This article has been updated to report the total amount of funding in the round.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – FluimediX today said that it has closed a round of financing intended to support further development of its NanoCycler platform.

The Taastrup, Denmark-based firm raised DKK 6 million ($1.1 million) in the round that was led by Seed Capital Denmark. In addition, existing shareholders participated in the round.

FluimediX is developing the NanoCycler, a fully-automated diagnostic platform for rapidly measuring genetic mutations in patients. According to the firm's website, the system can conduct near-patient DNA-based testing in less than 15 minutes, from sample to result.

The firm, which was founded in 2003 and has its offices at the Danish Technical Institute, said that the funds from this round of financing would be dedicated to developing a test for warfarin metabolism.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.